A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Locally Advanced or Metastatic Pancreatic Cancer.
Phase of Trial: Phase II
Latest Information Update: 30 Apr 2014
At a glance
- Drugs Docetaxel (Primary)
- Indications Pancreatic cancer
- Focus Biomarker; Therapeutic Use
- Sponsors INSYS Therapeutics, Inc
- 10 Jun 2017 Biomarkers information updated
- 01 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Aug 2010 NeoPharm estimates this trial may be completed by the fourth quarter of this year, as reported in a company media release.